Exelixis, Inc. (LON:0IJO)

Market Cap	8.16B
Revenue (ttm)	1.73B
Net Income (ttm)	416.37M
Shares Out	n/a
EPS (ttm)	1.41
PE Ratio	19.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,136
Average Volume	3,233
Open	36.00
Previous Close	34.81
Day's Range	35.97 - 37.03
52-Week Range	17.42 - 34.39
Beta	n/a
RSI	63.44
Earnings Date	Feb 6, 2025

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1994
• Employees: 1,147
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IJO

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Financial numbers in USD